ArticleEmerging infectious diseases2025
Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Early clinical predictors of macrolide-resistant Mycoplasma pneumoniae pneumonia in hospitalized children during the 2024 outbreak in South Korea.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Post-pandemic surge ofJournal of clinical microbiology · 2026Article
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Mycoplasma pneumoniae infection impairs asthma control in pediatric patients and exacerbates allergic airway inflammation.Respiratory research · 2026Article
- Molecular insights into macrolide resistant Mycoplasma pneumoniae isolates from outpatient clinics in Tehran, Iran.Scientific reports · 2026Article
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- Economic burden ofFrontiers in public health · 2026Article
- Impact of COVID-19 on the epidemiological features of mycoplasma pneumoniae infection in children with community-acquired pneumonia in Ganzhou, China.Frontiers in immunology · 2026Article
- Doxycycline treatment for drug-resistantFrontiers in medicine · 2026Article
- A fever-based therapeutic window for bronchoscopy to prevent bronchiolitis obliterans in children with Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period.Frontiers in cellular and infection microbiology · 2026Article
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Prevalence of Macrolide-Resistant Mycoplasma pneumoniae Infections After the COVID-19 Pandemic in Southern Italy, 2023-2025.Infectious diseases and therapy · 2025Article
- Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA.Emerging infectious diseases · 2025Article
- Mycoplasma pneumoniae in hospitalised children in the post-COVID era: clinical outcomes from a Turkish multicenter cohort.European journal of pediatrics · 2025Article
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Article
- Whole genome sequencing confirmed theASM case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae infections decreased in Ohio, USA, during the COVID-19 pandemic but reemerged in 2023; >2,000 cases were reported during September 2023--September 2024. Of 995 M. pneumoniae-positive samples, 24 (2.4%) had mutations for macrolide-resistant M. pneumoniae (MRMp). MRMp rates are low but increasing. MRMp surveillance is crucial for monitoring antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.